We assessed the cerebrospinal fluid (CSF) by flow cytometry and cytology in 51 newly diagnosed and 9 treated aggressive B-cell lymphomas at risk of central nervous system (CNS) involvement to examine the utility of flow cytometry, incidence of CSF disease and clinical surrogates of CNS spread. Multicolor flow cytometry using multiple antibody panels for light chains and B-and T-cell antigens identified neoplastic clones that comprised as little as 0.2% of total CSF lymphocytes. Among 51 newly diagnosed patients, 11 (22%) had occult CSF involvement. All 11 were detected by flow cytometry but only one by cytology (p 2 = 0.002).
INTRODUCTION

Secondary involvement of the central nervous system (CNS) by aggressive B-cell
lymphomas is an infrequent but nearly always fatal complication 1 . Although prophylactic treatment likely reduces the incidence of central nervous system relapse, it increases the toxicity of systemic chemotherapy and is unnecessary in most patients [1] [2] [3] . This has led to the development of clinical risk paradigms to identify patients who might benefit from central nervous system prophylaxis, but even among these patients, only a minority ever develop central nervous system disease 1 . The risk of central nervous system spread appears to be particularly high among patients with acquired immunodeficiency related-lymphoma (ARL), where it is a major cause of treatment failure, and has led some investigators to recommend routine prophylaxis in all patients 4, 5 . Nevertheless, like other aggressive B-cell lymphomas, only a minority of ARLs spread to the central nervous system and are not accurately predicted by clinical risk paradigms.
These findings indicate a need to develop and validate sensitive analytical methods for occult central nervous system lymphoma to ensure optimal treatment, while reducing unnecessary prophylactic treatment. Indeed, successful management of central nervous system involvement requires early detection and treatment, as well as reliable measures of treatment response 6 . Unfortunately, cytological examination of the cerebrospinal fluid, the diagnostic "gold standard", has a low sensitivity with a reported false negative rate of 20% to 60% 7, 8 . This has been ascribed to the paucity of tumor cells in the cerebrospinal fluid of patients with minimal disease and to the presence of confounding reactive lymphocytes. These results suggest that patients with low volume disease, who are likely to benefit most from treatment, are more likely to be falsely negative.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Flow cytometry is an objective and quantitative method ideally suited to identifying small populations of cells with aberrant phenotypes 9 . Methodologically, flow cytometry can detect aberrant B-cells that comprise as few as 0.01% of total lymphocytes, a sensitivity capable of detecting occult cerebrospinal fluid involvement 10 . To help validate flow cytometry and to assess the clinical correlates of central nervous system involvement, we assessed all newly diagnosed and relapsed aggressive B-cell lymphomas at risk of central nervous system lymphoma by cerebrospinal fluid cytology and flow cytometry and brain imaging since 1999.
Herein, we report our findings on the incidence and clinical risk factors for occult cerebrospinal fluid involvement and compare the sensitivity of flow cytometry and cytology.
MATERIALS AND METHODS
Patients and Treatment
Beginning in 1999, flow cytometry was employed for the analysis of all cerebrospinal fluid specimens obtained from patients with aggressive B-cell lymphoma. Patients' histology and cytology were reviewed by ESJ and AA and associates, respectively, and all patients were treated on an Institutional Review Board approved protocol and gave written informed consent.
In this study, we defined "occult" involvement of the cerebral spinal fluid by lymphoma as specimens negative by conventional cytology but positive by flow cytometry.
Between 1999 and 2004, 92 patients with newly diagnosed aggressive B-cell lymphomas of diffuse large B-cell (DLBCL) and Burkitt's histologies were treated at the National Cancer Institute. Of these patients, 51 (55%) were considered to be at high risk of central nervous system disease, as defined in the Results, and underwent central nervous system evaluation. An additional 9 patients with relapsed/treated DLBCL also underwent evaluation due to symptoms For personal use only. on August 31, 2017. by guest www.bloodjournal.org From or high risk of central nervous system involvement. The cerebrospinal fluid was obtained by lumbar puncture and was evaluated using standard methods including glucose, total protein, evaluation for infectious organisms as appropriate and cytology, and the central nervous system was imaged by MRI or CT.
Newly diagnosed patients with a diagnosis of DLBCL or Burkitt's lymphoma were entered on one of three different protocols containing dose-adjusted (DA)-EPOCH (infusional etoposide, vincristine and doxorubicin, with bolus prednisone and cyclophosphamide) or DA-EPOCH with rituximab, as previously reported, depending on the treatment date and HIV status 5, 11 . Patients with recurrent lymphomas received salvage treatment appropriate for the clinical setting. The newly diagnosed patients who were at risk of central nervous system lymphoma but had no evidence of disease received prophylactic treatment with 12 mg of intrathecal methotrexate on days 1 and 5 of cycles 3-6 (total 12 doses) of DA-EPOCH. Patients requiring active treatment for leptomeningeal lymphoma received: 12 mg of intrathecal methotrexate on the following schedule: Induction: twice weekly until 2 weeks past the last negative cerebrospinal fluid flow cytometry with a minimum of 4 weeks treatment; Consolidation: Six weekly treatments; Maintenance: Four monthly treatments. Modifications of this treatment plan, which included the use of cytarabine and/or cranial radiation, were made in patients who did not adequately respond, had excess toxicity and/or had parenchymal brain lesions, as clinically indicated. Among the newly diagnosed patients with evidence of cerebral spinal fluid lymphoma, treatment was administered via lumbar puncture in 7 and via Ommaya reservoir in 3 patients. All three relapsed patients received treatment via an Ommaya reservoir.
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Cytology Analysis
Cerebrospinal fluid samples were prepared in a manner to optimize cellular preservation and cellular concentration, while minimizing peripheral blood contamination. Fresh cerebrospinal fluid specimens were refrigerated and processed within several hours of collection as follows: 0.5ml of straight specimen were cytocentrifuged at 700 rpm for 15 minutes, and then utilized for a preliminary cytospin which was air-dried and stained with Diff-Quik (Dade, guada, PR). Based on the concentration of cells on the cytospin, samples were concentrated or diluted in RPMI 1640 (Gibco, BRL, Grand Island, NY).
Each case was interpreted by a cytopathologist (AF and AA). Results were reported as negative, positive, atypical or suspicious for malignant lymphoma based on cellular morphology and were independently reviewed from the flow cytometry results. Samples reported as "Negative for malignant cells" contained benign appearing lymphocytes and monocytes. Samples reported as showing "atypical lymphocytes" contained lymphocytes with abnormal nuclear cytoplasmic ratios, irregular nuclear morphology and possibly nucleoli. In these cases, the morphology was indeterminate between reactive and a neoplastic etiology. "Suspicious for malignant lymphoma" was reported when the lymphocytes were large, with increased nuclear:cytoplasmic ratios, irregular nuclear contours and prominent nucleoli. In these instances although a malignant etiology was favored, either due to the small number of cells or the remote possibility that these cells could be of a reactive etiology, the samples were not definitively called malignant. The diagnosis of "malignant lymphoma" was used when the cells exhibited the characteristic malignant morphology in keeping with the known histology.
Immunohistochemistry was not employed in the negative or suspicious cases because the number of cells was too low for this technique to be useful. 
Statistical Methods
Comparisons of dichotomous parameters were made between cerebrospinal fluid positive and negative patients using Fisher's exact test, while ordered categorical parameters were evaluated for the statistical significance of their association with cerebrospinal fluid positive or negative outcomes using the Cochran-Armitage trend test 13 . Continuously measured parameters were compared between groups using the Wilcoxon rank sum test. Logistic regression analysis was used to further evaluate whether any factors were jointly associated with a classification to positive or negative results. Finally, McNemar's test for paired categorical data was used to determine the degree to which there is concordance or discordance between flow cytometry and cytology results on the same individual. All p-values are two-tailed, and have not been adjusted for multiple comparisons.
RESULTS
Patient Characteristics
Of 92 consecutive patients with newly diagnosed aggressive lymphoma, 51 (55%) underwent evaluation of the cerebrospinal fluid based on clinical features associated with an increased risk of central nervous system involvement by lymphoma (Table 2) 1 . These clinical features included a diagnosis of AIDS-related lymphoma (ARL) in 23/51 (45%) patients, and among 28 HIV negative patients, a diagnosis of Burkitt's lymphoma in 6 (21%) or a diagnosis of DLBCL with at least 2 extranodal disease sites and elevated lactate dehydrogenase (LDH) or bone marrow involvement in 22 (79%) patients. Expectedly, there was a modest enrichment of adverse prognostic factors among patients undergoing cerebrospinal fluid evaluation, compared to the entire cohort of patients with aggressive lymphomas (Table 2 ). These factors include elevated LDH in 75% and 2 extranodal sites in 53% of patients, which comprise previously identified risk factors for central nervous system spread 1, 14 .
We also examined a separate group of 9 patients with relapsed/treated DLBCL who underwent cerebrospinal fluid evaluation due to suspected central nervous system disease or were considered to be at high risk (Table 3 ). The distribution of adverse prognostic features was similar to that found in the entire cohort of untreated patients with the exception of an increased number of AIDS related lymphomas. Overall, 3 patients with relapsed disease had positive cerebrospinal fluid findings, all of whom were HIV positive and had extranodal disease sites at initial diagnosis.
Cerebrospinal Fluid Analysis
We examined the cerebrospinal fluid laboratory characteristics and analyzed their relationship with the detection of cerebrospinal fluid lymphoma (Table 4) . Among the 51 newly diagnosed patients, there was no association between the cerebrospinal fluid total protein, WBC and RBC and the presence or absence of cerebrospinal fluid lymphoma. Notably, the cerebrospinal fluid total protein was elevated (> 45 mg/dl) in 40% and 30% of patients with and without cerebrospinal fluid involvement, respectively, and hence was not a discriminating measure. Similarly, the total WBC was not useful, even on an individual patient basis, and was increased above 10 cells/µL in 3 patients with and in one patient without cerebrospinal fluid involvement. While recognizing the number of patients with relapsed/treated disease is small, the laboratory values in this group were also not significantly discriminating (Table 4) .
Disease Detection by Flow Cytometry versus Cytology
We analyzed the cerebrospinal fluid by cytology and flow cytometry for the presence of lymphoma cells in the 51 newly diagnosed patients (Table 5) . In these cases, cerebrospinal fluid staging evaluation was performed based on a clinical central nervous system risk paradigm, although two patients each in the positive and negative groups also had neurological symptoms.
Flow cytometry detected an abnormal B-cell population, consistent with lymphoma, in 11 of 51 (22%) patients, whereas cytology alone detected an abnormal population in only one of these 11 patients (p 2 =0.0020) ( Table 5 ). The low detection rate of cytology in these patients reflects the low median percent of tumor cells (7%; range: 0.2-99) within the concentrated cerebrospinal fluid specimen of these mostly asymptomatic patients (Table 4) . Of note, the single patient detected by both cytology and flow cytometry was asymptomatic but had the highest
The cerebrospinal fluid from the relapsed/treated patients was also analyzed by both flow cytometry and cytology for evidence of lymphoma (Table 5) . In these cases, flow cytometry was also more sensitive than cytology and was positive in 3 cases, whereas cytology was positive in one case and suspicious in another case (Table 6 ). Compared to the newly diagnosed patients, these patients had a high median concentration of 62350 (range: 700-124000) lymphoma cells/ml within the concentrated cerebrospinal fluid specimen. This increased number of cells reflects the presence of symptomatic leptomeningeal disease in some of these patients and accounts for the ability of cytology, which is less sensitive than flow cytometry, to detect disease in some of these cases.
To help assess the potential impact of the flow cytometry results on the cytology results and for quality assurance, the same cytologists (AF and AA) undertook a retrospective review of the cerebrospinal fluid cytology from the 11 newly diagnosed patients with leptomeningeal disease. Overall, the cytology was changed for one case from negative to positive and one case was changed from showing atypical cells to "highly suspicious". These results indicate that the concentration of tumor cells in asymptomatic patients is generally below the level of adequate detection by cytology and that flow cytometry is required for early disease detection.
Flow Cytometry Analysis of Cerebrospinal Fluid
Cerebrospinal fluid flow cytometry should be interpreted within the context of the patient's histological diagnosis, and is dependent on the analysis of light chain restriction and/or aberrant antigen expression [15] [16] [17] . Light chain restriction alone is sufficient to establish the presence of a monoclonal population, and was present in 11 (79%) of the 14 positive cases from the current series (Table 6 ). Furthermore, among these 11 cases, the tumor biopsies showed the same light chain restriction in 4 (36%) and were unavailable in the 7 remaining cases. As shown for case 10, expression of a single immunoglobulin light chain produces a readily identifiable unimodal staining pattern ( Figure 1A) . It is not uncommon, however, for aggressive B-cell lymphomas to lack surface immunoglobulin expression, which in itself is a highly abnormal finding 16, 18 . In these instances, demonstration of a homogeneous population of large surface Figure 1D) 12, 16, 18 .
Prognostic Factors and Clinical Outcome
To identify the clinical characteristics associated with cerebrospinal fluid involvement in the 51 patients at risk of central nervous system involvement, we performed a univariate and logistic regression analysis of the characteristics listed in Table 2 . The presence of two or more extranodal sites was the only evaluated parameter which was associated with cerebrospinal fluid involvement (p 2 =0.0057; Table 2 
DISCUSSION
In the present report, flow cytometry was able to detect occult cerebrospinal fluid lymphoma in 11/51 (22%) of newly diagnosed aggressive B-cell lymphoma patients who were at increased clinical risk of developing central nervous system involvement. In contrast, cytology was not sufficiently sensitive to detect this low level involvement by neoplastic cells.
Quantitatively, flow cytometry detected a neoplastic clone that comprised as little as 0.2% of the concentrated cellular pellet in the present study, whereas cytology generally requires that neoplastic cells comprise at least 5% of cells 10, 17, 19, 20 . Of course, this is dependent on the tumor phenotype and histology for these respective methods 17 . Perhaps not surprisingly, there was no difference in the cerebrospinal fluid laboratory characteristics among patients with or without occult cerebrospinal fluid involvement, indicating that low concentrations of neoplastic cells do not significantly impact these parameters, and highlighting their low utility in this setting. On the other hand, cytology was able to detect cerebrospinal fluid involvement in patients with relapsed/treated disease, where the median percent of neoplastic cells was higher than that found in the newly diagnosed patients.
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Cytology is considered the method of choice for detection of B-cell neoplasms in the cerebrospinal fluid, but two small studies have shown flow cytometry can increase detection sensitivity when combined with cytology 10, 20 . In these two studies of 10 and 9 positive cases, respectively, 3 cases each were detected by flow cytometry alone with the remaining cases also detected by cytology. In the present study, however, 10 of 11 cases from newly diagnosed patients were detected by flow cytometry alone, indicating that cytology is inadequate for cerebrospinal fluid staging of newly diagnosed aggressive B-cell lymphomas. The higher rate of concordance between cytology and flow cytometry in the two published studies almost certainly reflects the clinical practice of sampling cerebrospinal fluid in symptomatic patients and not for staging purposes. In the former setting, the tumor cell concentration will be relatively high and hence usually detectable by both cytology and flow cytometry, as we found in our relapsed/treated patients.
These results raise important questions regarding the optimal management of patients at increased risk of central nervous system involvement by aggressive B-cell lymphoma. The phenomenon of central nervous system involvement by diffuse large B-cell lymphomas is incontrovertible, and is clinically observed in 5% of unselected patients and 8% of high risk patients that do not receive central nervous system penetrating agents 1, 3, 22 .
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